Trial Profile
Post-Marketing Surveillance of Perjeta in Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary)
- Indications Advanced breast cancer; Early breast cancer
- Focus Adverse reactions
- Sponsors Roche
- 30 Apr 2021 Status changed from active, no longer recruiting to completed.
- 26 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 05 Mar 2021 Planned End Date changed from 28 Feb 2021 to 28 May 2021.